Royalty tells Elan never mind; court invalidates Novo Prandin patent; AMA take on obesity good for Qsymia, Belviq;

@FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit Court, $200m sales at risk. Report | Follow @FiercePharma

@EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce

> Royalty Pharma threw in the towel Tuesday, dropping its four-month, $6.7 billion takeover run for Irish drug company Elan ($ELN). Story

> Actavis ($ACT) and Kissei Pharmaceutical are suing Sandoz and Hetero for infringing the patent on Rapaflo, a treatment for benign prostatic hyperplasia (BPH). Release

> The two thrombosis drug brands, Arixtra and Fraxiparine, that GlaxoSmithKline ($GSK) is talking about selling to South Africa's Aspen Pharmacare could be worth $1 billion. Story

> A U.S. court has slapped down a patent for Novo Nordisk's ($NVO) Prandin, a move that paves the way for generics of the combo with metformin for treating diabetes. Story

> Protalix BioTherapeutics said Wednesday that it has a 7-year deal with Brazil to sell the country $280 million worth of its Gaucher disease drug, Uplyso, known as Elelyso in the U.S. Story

> Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN) reported today that results of a study looking for additional benefits for their Type 2 diabetes drug Onglyza found that it was no better than a placebo at reducing heart attacks, strokes, or death from cardiovascular causes. Story

Medical Device News

@FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev

@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce

> Techne grabs Bionostics for $104M. Item

> Terumo adding 400+ jobs in R&D expansion. Report

> CryoLife eyes FDA approval for dissolving hemostat. Item

> Mirabilis nabs up to $13M for uterine fibroid device. Report

> OrthoSensor wins FDA nod for knee tech. Article

Biotech News

@FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech

 @JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce

@RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce

 @EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce

> Sarepta shares spike on upbeat results from DMD extension study. News

> NIH backs pharma giants and academics' projects to revive R&D castoffs. Article

> Analysis: AMA decision on obesity will boost drug R&D in a troubled field. Editor's corner

> Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround. Story

Drug Delivery News

@MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce

> BD, JDRF partner to join artificial pancreas race. More

> Capsugel launches Lipidex platform for greater oral stability, potency. Item

> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article

> Drug-carrying "nanovolcanoes" make precise delivery structures. Story

And Finally... The American Medical Association (AMA) kicked aside a committee recommendation and voted to designate obesity a disease, a move that may boost the fortunes of the new obesity drugs, Qysmia from Vivus ($VVUS) and Belviq from Arena ($ARNA). Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.